AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06264427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).
Study NCT05458765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir alafenamide
Description: 200mg/25mg tablet, once daily dosing for 24 weeks
Study NCT05458765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet
Description: 200mg/300mg tablet, once daily dosing for 24 weeks
Study NCT05161533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05161533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT05161533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT05161533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT05161533 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study NCT05161533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05161533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06427200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Iron
Description: oral iron once daily during or after meals as add-on therapy for 12 weeks.
Study NCT06427200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: lactoferrin twice daily before meals as add-on therapy for 12 weeks.
Study NCT06427200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactoferrin and oral iron
Description: lactoferrin twice daily before meals and oral iron once daily during or after meals as add-on therapy for 12 weeks.
Study NCT04770389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib 5mg
Description: tablet
Study NCT04770389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg
Description: tablet
Study NCT04770389 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study NCT05248568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core training
Description: Core training lasts for 12 weeks, three times a week, one hour each time
Study NCT05645874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsy
Description: Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
Study NCT05517395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health nutrition education
Description: The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.
Study NCT05517395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
Study NCT06226350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
Description: F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.
Study NCT05273034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1-hour sepsis bundle
Description: The sepsis management will be delivered in a timely manner within 60 minutes of ED triage including~* usual test and treatment~* blood culture~* lactate measurement~* broad spectrum antibiotics~* In case of hypotension or lactate > 4, rapid administration of 30ml/kg crystalloid fluid resuscitation will be mandated~* In case of initial elevated lactate (> 2 mmol/l), a second lactate measurement should be done after initial fluid resuscitation.
Study NCT04455763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SVF
Description: Adipose-derived stromal vascular fraction
Study NCT04455763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint
Description: Thumb brace (Actimove® Rhizo Forte)
Study NCT04455763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splint
Description: Thumb brace (Actimove® Rhizo Forte)
Study NCT04549870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast
Description: Treatment according to national roflumilast guidelines
Study NCT04549870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Treatment according to national roflumilast guidelines
Study NCT04777136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit and comprehensive geriatric assessment
Description: Home-visit from the geriatric team, who will do a full geriatric assessment and targeted interventions
Study NCT04777136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group, no designated follow up
Description: Only follow-up on patients own initiative with contact to the general practitioner
Study NCT05602038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus laborum block
Description: quadratus lumborum block will be performed using ultrasound machine (Sonosite Portable Ultrasound System, SonoSite, Bothell, Washington, USA). A 5-8 MHZ curved probe will be used with the patient positioned on the lateral side
Study NCT05602038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg
Study NCT05602038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal bupivacaine
Description: intrathecal bupivacaine 0.5% 15mg and fentanyl
Study NCT05602038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal bupivacaine
Description: intrathecal bupivacaine 0.5% 15mg and fentanyl
Study NCT06265857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
Study NCT06265857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Study NCT06265857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06265857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06497348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy and exercises (experimental group) or only exercises (control group) in people with frozen shoulder
Description: They will be divided into two groups, one experimental (they will be mobilized and given exercises to see whether or not they gain joint range in the different movements of flexion-extension, abduction-adduction and internal rotation-external rotation) and another control group ( The patients will be blindly evaluated and they will be given the same exercises as the experimental group)
Study NCT06497348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy and exercises (experimental group) or only exercises (control group) in people with frozen shoulder
Description: They will be divided into two groups, one experimental (they will be mobilized and given exercises to see whether or not they gain joint range in the different movements of flexion-extension, abduction-adduction and internal rotation-external rotation) and another control group ( The patients will be blindly evaluated and they will be given the same exercises as the experimental group)
Study NCT04591275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB807 Injection
Description: mAb targeting RANKL, human monoclonal antibody targeting RANKL
Study NCT04591275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: mAb targeting RANKL, human monoclonal antibody targeting RANKL
Study NCT00013208 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Case Management
Study NCT04841421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-CD147
Description: The 89Zr-CD147 is a promising positron emission tomography probe and it is possible to select suitable tumor patients with CD147 expression to benefit from anti-CD147 treatment.
Study NCT05166629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eatable Alphabet
Description: Eatable Alphabet is a set of kitchen activity cards developed by ChopChop Family, in collaboration with the American Academy of Pediatrics, with funding from the CDC (https://www.chopchopfamily.org/eatable-alphabet/). It includes a series of alphabet cards with family-friendly recipes.
Study NCT05166629 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Please see above description of usual care.
Study NCT06396078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1000 MG
Description: Ceftriaxone 1 g IV q 24 hours x 7 days (in addition to clarithromycin and metronidazole)
Study NCT06396078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Clarithromycin 500 mg PO BID x 7 days (in addition to ceftriaxone and metronidazole)
Study NCT06396078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Description: Metronidazole 500 mg PO q 12 hours x 7 days (in addition to clarithromycin and ceftriaxone)
Study NCT06396078 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ampicillin 2 GM Injection
Description: Ampicillin 2 g IV q 6 hours x 48 hours (prior to amoxicillin and in addition to either azithromycin or erythromycin)
Study NCT06396078 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin 250 MG
Description: Amoxicillin 250 mg q 8 hours for an additional 5 days (following ampicillin and in addition to either azithromycin or erythromycin)
Study NCT06396078 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Azithromycin 1 g PO x 1 dose (in addition to ampicillin and amoxicillin)
Study NCT06396078 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erythromycin
Description: Erythromycin 250 mg IV q 6 hours x 48 hours followed by erythromycin 333 mg PO TID for an additional 5 days (in addition to ampicillin and amoxicillin)
Study NCT05442099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iso-principle music playlist
Description: Participants listen to the iso-principle music playlist for 30 minutes.
Study NCT05442099 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Generic calm music playlist
Description: Participants listen to the calm music playlist for 30 minutes.
Study NCT06354114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2011
Description: IV infusion, 260 mg/m\^2
Study NCT05901493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual category training
Description: Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories
Study NCT04755348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: A 4mg nicotine pouch product
Study NCT04755348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: A 4mg nicotine pouch product
Study NCT04755348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 2mg nicotine lozenge product
Study NCT04755348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: A 2mg nicotine lozenge product
Study NCT04755348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: A 2mg nicotine lozenge product
Study NCT04755348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: A 2mg nicotine lozenge product
Study NCT05534425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GenX intergenerational mentoring program
Description: GenX trains older adults to collaborate with K-3rd grade teachers in mentoring high-need elementary school students in core reading and math skills.
Study NCT05534425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GenX intergenerational mentoring program
Description: GenX trains older adults to collaborate with K-3rd grade teachers in mentoring high-need elementary school students in core reading and math skills.
Study NCT06199609 — intervention group
Intervention type: PROCEDURE
Intervention: Hemodialysis pathway
Description: AVF and TCC are two different vascular pathways for hemodialysis
Study NCT06199609 — intervention group
Intervention type: PROCEDURE
Intervention: AVF
Description: Left atrial changes caused by AVF establishment
Study NCT06199609 — intervention group
Intervention type: PROCEDURE
Intervention: AVF
Description: New onset atrial fibrillation caused by AVF establishment
Study NCT02014350 — intervention group
Intervention type: DEVICE
Intervention: DePuy Delta Xtend Reverse TSA
Study NCT05988450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQ-Kyrin Transcatheter Mitral Valve Repair System
Description: Transcatheter mitral valve clip placement to repair the valve and correct regurgitation.
Study NCT04701138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SPM Active
Description: Each capsule contains 145 mg of SPMs (fractionated marine lipids standardized to 18-HEPE, 14-HDHA, and 17-HDHA). All subjects will take 4 capsules orally each day for a total daily dose of 580 mg.
Study NCT05549700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromodulation
Description: Ultrasound-guided percutaneous neuromodulation will be applied. The protocol used was 5 seconds of stimulation, 55 seconds of rest for 5 minutes at a frequency of 100 Hz and a phase duration of 350 microseconds
Study NCT04758442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional blood sample
Description: Included subjects will provided three blood samples to follow vancomycin concentration
Study NCT04957576 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Visuo-tactile stimulation
Description: The patient will place both hands on a table in front of him/her, seeing only the left one disown. A visuo-tactile stimulation will be done, with the right (out of view, but perceiving the tactile stimulation) and left (in full view, but with somato-sensory deficits, therefore not feeling the stimulation) hands touched with a paintbrush for five minutes.
Study NCT04957576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuo-tactile stimulation
Description: The patient will place both hands on a table in front of him/her, seeing only the left one disown. A visuo-tactile stimulation will be done, with the right (out of view, but perceiving the tactile stimulation) and left (in full view, but with somato-sensory deficits, therefore not feeling the stimulation) hands touched with a paintbrush for five minutes.
Study NCT04856787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701、 BP102 、XELOX
Description: Phase 2：Single Group~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
Study NCT04856787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701、 BP102 、XELOX
Description: Phase 3：Randomized~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
Study NCT04856787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo、 BP102、 XELOX
Description: Phase 3：Randomized~Drug:Placebo 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
Study NCT06201897 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACTH/Oral Steroids
Description: Injection ACTH or Oral Steroids in children with West Syndrome
Study NCT05926388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-assisted training
Description: Patients will be given training on insulin therapy and management using lecture, question-answer, video and demonstration methods.
Study NCT05507775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet
Description: Participants will be treated with digoxin tablets for 3 weeks. On the first they, participants will start with a starting dosage of 3x0.25mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.25mg. Participants aged >70 years or with body weight \<55kg will initiate a starting dosage of 3x0.125mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.125mg.~After one week the blood concentration of digoxin will be measured. According to this blood concentration, the dose of digoxin will be adjusted.
Study NCT05439486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.
Description: ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
Study NCT05439486 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.
Description: ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.